Bessemer Group
CNCE

Bessemer Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Bessemer Group’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-36,700
Closed -$365K – 1740
2020
Q2 		$365K Buy
+36,700
New +$352K ﹤0.01% 1040

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LC
L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bessemer Group's CNCE Position: Q3 2020 in Review

Bessemer Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2020, closing a stake of 36,700 shares — an estimated $365K sold.

Bessemer Group first reported a position in CNCE in Q2 2020 and held it in 1 quarter. The position peaked at $365K in Q2 2020. 92 funds tracked by Wall St. Rank hold CNCE as of Q3 2020.

  • Bessemer Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Bessemer Group sold 36,700 Concert Pharmaceuticals, Inc. shares in Q3 2020, an estimated $365K.
  • Bessemer Group first reported a position in Concert Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Bessemer Group's Concert Pharmaceuticals, Inc. position peaked at $365K in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.